CDT Equity Inc.: financial analysis
Ratios worked out from 5 fiscal years of CDT Equity Inc.'s statements, compared with 665 companies in Biotechnology.
CDT Equity Inc. scorecard#
Passes 1 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 3
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- –Free cash flow yield above 5%No free cash flow yield on file.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growthnot known
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 1
- ✗Profitable in the newest year-$39 MNet income -$39 M in fiscal 2025.
- –Profitable in each of the last five yearsFive years of net income are not on file.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 3
- ✗Short-term assets cover short-term liabilities0.3×Current ratio 0.34 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-183.8×Operating income -183.8 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns1 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- ✓Dividends and buybacks above 3% of the market value73.3%Dividends and buybacks were 73.3% of the market value.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Net loss of $39 million, the 4th loss-making year in a row.
- Shareholders' equity is negative: -$7 million.
- Operating income covers the interest bill only -183.8 times.
- Liabilities due within a year exceed current assets (current ratio 0.34).
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
2of 5(4 of the nine tests cannot be worked out from the statements on file, so there is no full score)
- Made a profitno
- Operations brought in cashno
- Return on assets roseno
- Cash from operations exceeds profityes
- Long-term debt fell against assetsnot on file
- Current ratio roseyes
- No new shares issuednot on file
- Gross margin rosenot on file
- Asset turnover rosenot on file
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Return on assets | -797.2% | -312.0% | -15.0% | — | — | -44.4% | 0% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Interest cover | -183.80× | -514.00× | — | -31.60× | — | -22.77× | 16% | |
| Current ratio | 0.34× | 0.25× | 3.18× | 0.16× | 0.53× | 4.39× | 6% | |
| Equity share of assets | -126.9% | -162.1% | -6.4% | — | — | 64.7% | 6% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | — | $-10 M | — | — | — | $-40 M | — |
How each figure is worked out#
- Return on assets
- Net income as a share of total assets (average of the year).
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Shareholder yield
- Dividends plus buybacks as a share of today's market value.